Rani Therapeutics Holdings RANI
NASDAQ RANI
$0.81 +0.01 (+1.25%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rani Therapeutics Holdings (RANI) Other Accumulated Expenses (2022 - 2024)

Updated

Rani Therapeutics Holdings' Other Accumulated Expenses came in at $931,000 for Q4 2024, up 86.2% from $500,000 a year earlier.

Analysis

Rani Therapeutics Holdings (RANI) Other Accumulated Expenses (2022 - 2024) Analysis & Trends

  • Going back by year, Other Accumulated Expenses was $500,000 in FY2023 (+624.6%) and $69,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Rani Therapeutics Holdings 151.61 Mn 160.36 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 931,000.00
Dec 31, 2023 500,000.00
Dec 31, 2022 69,000.00
API Access

Rani Therapeutics Holdings Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=RANI&period=max&api_key=YOUR_API_KEY